### **ISTH ACADEMY WEBINAR**

International Society on Thrombosis and Haemostasis

## THROMBOSIS, THROMBOPROPHYLAXIS AND COAGULOPATHY IN COVID- 19 INFECTIONS



ademv

MY.ISTH.ORG



**Prof Beverley Hunt** M.D., O.B.E.

King's College London (U.K.)

**Prof Marcel Levi** M.D., Ph.D.

University College Hospital (U.K.)

**Simon Stanworth** Ph.D.

John Radcliffe Hospital (U.K.)




University College London Hospitals

## **Coagulopathy of COVID-19**



Marcel Levi University College London, UK



ORIGINAL ARTICLE

### Clinical Characteristics of Coronavirus Disease 2019 in China

W. Guan, Z. Ni, Yu Hu, W. Liang, C. Ou, J. He, L. Liu, H. Shan, C. Lei, D.S.C. Hui,
B. Du, L. Li, G. Zeng, K.-Y. Yuen, R. Chen, C. Tang, T. Wang, P. Chen, J. Xiang,
S. Li, Jin-lin Wang, Z. Liang, Y. Peng, L. Wei, Y. Liu, Ya-hua Hu, P. Peng,
Jian-ming Wang, J. Liu, Z. Chen, G. Li, Z. Zheng, S. Qiu, J. Luo, C. Ye, S. Zhu,
and N. Zhong, for the China Medical Treatment Expert Group for Covid-19\*

This article was published on February 28, 2020, and last updated on March 6, 2020, at NEJM.org.

### Clinical Characteristics of Coronavirus Disease 2019 in China

Variable	All Patients (N = 1099)			Presence of Composite Primary End Point	
		Nonsevere (N = 926)	Severe (N=173)	Yes (N=67)	No (N=1032)
Platelet count					
Median (IQR) — per mm <sup>3</sup>	168,000 (132,000–207,000)	172,000 (139,000–212,000)	137,500 (99,000–179,500)	156,500 (114,200–195,000)	169,000 (133,000–207,000)
Distribution — no./total no. (%)					
<150,000 per mm <sup>3</sup>	315/869 (36.2)	225/713 (31.6)	90/156 (57.7)	27/58 (46.6)	288/811 (35.5)
Median hemoglobin (IQR) — g/dl‡	13.4. (11.9–14.8)	13.5 (12.0–14.8)	12.8 (11.2–14.1)	12.5 (10.5-14.0)	13.4 (12.0–14.8)
D-dimer≥0.5 mg/liter	260/560 (46.4)	195/451 (43.2)	65/109 (59.6)	34/49 (69.4)	226/511 (44.2)

### Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Fei Zhou\*, Ting Yu\*, Ronghui Du\*, Guohui Fan\*, Ying Liu\*, Zhibo Liu\*, Jie Xiang\*, Yeming Wang, Bin Song, Xiaoying Gu, Lulu Guan, Yuan Wei, Hui Li, Xudong Wu, Jiuyang Xu, Shengjin Tu, Yi Zhang, Hua Chen, Bin Cao


	Non survivor (n=54)	Survivor (n=137)	
Lymphocytes < 0.8x10 <sup>9</sup> /L	41 976%)	36 (26%)	<0.0001
Platelet count <100x10 <sup>9</sup> /L	1 (20%)	2 (1%)	<0.0001
LDH (IU)	521 (98%)	253 (54%)	<0.0001
Troponin I (> 28 pg/ml)	46%	1%	<0.0001
Prothrombin time (>16s)	13%	3%	-
Serum ferritin ug/L	1435 (96%)	503 (71%)	0.0008
IL-6 pg/ml	11 (7-14.5)	6.3 (5.0-7.9)	<0.0001
D Dimer >1 ug/ml	81%	24%	<0.0001





# Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia


Ning Tang<sup>1</sup> | Dengju Li<sup>2</sup> | Xiong Wang<sup>1</sup> | Ziyong Sun<sup>1</sup>


Parameters	Normal range	Total (n = 183)	Survivors (n = 162)	Non-survivors (n = 21)	P values
Age (years)		54.1 ± 16.2	52.4 ± 15.6	64.0 ± 20.7	<.001
Sex (male/female)		98/85	82/80	16/5	.035
With underlying diseases		75 (41.0%)	63 (38.9%)	12 (57.1%)	.156
On admission					
PT (sec)	11.5-14.5	13.7 (13.1-14.6)	13.6 (13.0-14.3)	15.5 (14.4-16.3)	<.001
APTT (sec)	29.0-42.0	41.6 (36.9-44.5)	41.2 (36.9-44.0)	44.8 (40.2-51.0)	.096
Fibrinogen (g/L)	2.0-4.0	4.55 (3.66-5.17)	4.51 (3.65-5.09)	5.16 (3.74-5.69)	.149
D-dimer (µg/mL)	<0.50	0.66 (0.38-1.50)	0.61 (0.35-1.29)	2.12 (0.77-5.27)	<.001
FDP (µg/mL)	<5.0	4.0 (4.0-4.9)	4.0 (4.0-4.3)	7.6 (4.0-23.4)	<.001
AT (%)	80-120	91 (83-97)	91 (84-97)	84 (78-90)	.096















Day after admission


## **COVID-19 coagulopathy: summary**

- Signs of coagulation activation mimicking DIC, but different from 'usual' sepsis-related DIC
  - Less prominent thrombocytopenia
  - Less consumption of coagulation proteins
- Clinical and pathological signs of thrombotic microangiopathy
  - vWF multimers and ADAMTS13 ?
- Prominent increase in D-dimer with predictive value for adverse outcome




### Mechanisms of Severe Acute Respiratory Syndrome Coronavirus-Induced Acute Lung Injury

Lisa E. Gralinski,<sup>a</sup> Armand Bankhead III,<sup>b</sup> Sophia Jeng,<sup>b</sup> Vineet D. Menachery,<sup>a</sup> Sean Proll,<sup>c</sup> Sarah E. Belisle,<sup>c</sup> Melissa Matzke,<sup>d</sup> Bobbie-Jo M. Webb-Robertson,<sup>d</sup> Maria L. Luna,<sup>d</sup> Anil K. Shukla,<sup>d</sup> Martin T. Ferris,<sup>e</sup> Meagan Bolles,<sup>f</sup> Jean Chang,<sup>c</sup> Lauri Aicher,<sup>c</sup> Katrina M. Waters,<sup>d</sup> Richard D. Smith,<sup>d</sup> Thomas O. Metz,<sup>d</sup> G. Lynn Law,<sup>c</sup> Michael G. Katze,<sup>c,g</sup> Shannon McWeeney,<sup>b</sup> Ralph S. Baric<sup>a,f</sup>



Plasminogen activator-driven pathways determine activation of the plasminogen-plasmin system and are an important factor in lethality



Iba T, et al, 2020

## Acute pulmonary embolism and COVID-19 pneumonia: a random association?


#### Gian Battista Danzi 💿 <sup>1</sup>\*, Marco Loffi 💿 <sup>1</sup>, Gianluca Galeazzi 🕞 <sup>1</sup>, and Elisa Gherbesi 🕞 <sup>2</sup>

<sup>1</sup>Division of Cardiology, Ospedale di Cremona, Cremona, Italy; and <sup>2</sup> Università degli Studi di Milano, Milano, Italy

\* Corresponding author. Division of Cardiology, Ospedale di Cremona, Viale Concordia 1, 26100 Cremona, Italy. Tel: +39 0372405333, Email: gbdanzi@tin.it

In a 75-year-old Covid-19positive woman hospitalized for severe bilateral pneumonia, CT scan documented bilateral pulmonary embolism associated with extensive groundglass opacifications involving both the lung parenchymas.

Acute infections are associated with a transient increased risk of venous thromboembolic events. A COVID-19positive 75-year-old woman, with severe bilateral pneumonia and concomitant acute pulmonary embolism, was hospitalized after 10 days of fever and a recent onset of dyspnoea. She was haemodynamically stable and without strong predisposing risk factors for venous thrombo-embolism.








ORIGINAL ARTICLE 🔂 Free Access

# Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy


Ning Tang, Huan Bai, Xing Chen, Jiale Gong, Dengju Li, Ziyong Sun 🔀

First published:27 March 2020 | https://doi.org/10.1111/jth.14817



Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Table 4 The association between heparin treatment and outcomes in stratified patients					
	28-day mortality		Univariate analysis		
Patients with	Treating with	Non-treating	Odds ratio	P value	
	Heparin	with heparin	(95% CI)		
SIC socre≥4 (n=97)	40.0%	64.2%	0.372	0.029	
			(0.154-0.901)		
SIC score≤4 (n=352)	29.0%	22.6%	1.284	0.419	
			(0.700-2.358)		



### Conclusion

- Severe COVID-19 infection is associated with a coagulopathy with features of both DIC and thrombotic microangiopathy
- Coagulopathy is at least a marker of adverse outcome
- Severe COVID-19 seems to result in a prohemostatic state with possible consequences for the incidence of venous thromboembolism

